On top of that, unregulated dosing and contamination can harm performance and health
TAKE THE NEXT STEP Begin Your Ethos Experience Schedule your complimentary consultation and discover the Ethos difference
Population Limitations: As noted previously, the trials did not include elderly individuals, pregnant women, children, or those with certain medical conditions
IGF-1 LR3's resistance to IGF binding proteins gives it a half-life measured in hours, which makes it suitable for study designs that need sustained systemic exposure or repeated-measures protocols where researchers want signaling active across a full observation day
EC50 12.7 ng/ml (1.4 nM)
8-12 Weeks: Long-term benefits become apparent, including enhanced tissue integrity, reduced scarring, and overall improved recovery